AEs reported for≥15% of patients in the overall treated population (N = 72) and all grade 3 or 4 events
| AE . | n (%) . | ||
|---|---|---|---|
| All grades . | Grade 3 . | Grade 4 . | |
| Fatigue | 60 (83.3) | 6 (8.3) | 0 |
| Constipation | 50 (69.4) | 1 (1.4) | 0 |
| Sensory neuropathy | 47 (65.3) | 4 (5.6) | 0 |
| Thrombocytopenia | 35 (48.6) | 7 (9.7) | 1 (1.4) |
| Nausea/diarrhea | 46 (63.9) | 1 (1.4) | 0 |
| Pneumonia/infections | 41 (56.9) | 10 (13.9) | 0 |
| Palmar-plantar erythrodysesthesia | 18 (25.0) | 0 | 0 |
| Neutropenia | 21 (29.2) | 12 (16.7) | 2 (2.8) |
| Cardiovascular | 11 (15.3) | 2 (2.8) | 0 |
| Painful neuropathy | 8 (11.1) | 0 | 0 |
| DVT/pulmonary embolism | 4 (5.6) | 1 (1.4) | 1 (1.4) |
| AE . | n (%) . | ||
|---|---|---|---|
| All grades . | Grade 3 . | Grade 4 . | |
| Fatigue | 60 (83.3) | 6 (8.3) | 0 |
| Constipation | 50 (69.4) | 1 (1.4) | 0 |
| Sensory neuropathy | 47 (65.3) | 4 (5.6) | 0 |
| Thrombocytopenia | 35 (48.6) | 7 (9.7) | 1 (1.4) |
| Nausea/diarrhea | 46 (63.9) | 1 (1.4) | 0 |
| Pneumonia/infections | 41 (56.9) | 10 (13.9) | 0 |
| Palmar-plantar erythrodysesthesia | 18 (25.0) | 0 | 0 |
| Neutropenia | 21 (29.2) | 12 (16.7) | 2 (2.8) |
| Cardiovascular | 11 (15.3) | 2 (2.8) | 0 |
| Painful neuropathy | 8 (11.1) | 0 | 0 |
| DVT/pulmonary embolism | 4 (5.6) | 1 (1.4) | 1 (1.4) |